Evidence map›Paper›PMID 37079135›Full record

ArticleEuropean journal of epidemiology2023

What is the role of puberty in the development of islet autoimmunity and progression to type 1 diabetes?

Essi J Peltonen, Riitta Veijola, Jorma Ilonen, Mikael Knip, Harri Niinikoski, Jorma Toppari, Helena E Virtanen, Suvi M Virtanen, Jaakko Peltonen, Jaakko Nevalainen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Essi J PeltonenUnit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland. essi.peltonen@tuni.fi.ORCID http://orcid.org/0000-0002-5782-3089
Riitta VeijolaDepartment of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland.
Jorma IlonenImmunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland.
Mikael KnipPediatric Research Center, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
Harri NiinikoskiResearch Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.
Jorma ToppariResearch Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.
Helena E VirtanenResearch Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.
Suvi M VirtanenUnit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Jaakko PeltonenFaculty of Information Technology and Communication Sciences, Tampere University, Tampere, Finland.
Jaakko NevalainenUnit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Tampere University · FIUniversity of Turku · FIOulu University Hospital · FIUniversity of Helsinki · FI

Funding

Academy of Finland 114666Academy of Finland 126813Academy of Finland 129492Academy of Finland 139391Academy of Finland 201988Academy of Finland 210632Academy of Finland 276475Academy of Finland 307996Academy of Finland 308065Academy of Finland 308066Academy of Finland 63672Academy of Finland 68292Academy of Finland 79685Academy of Finland 79686Academy of Finland 80846Academy of Finland Center of Excellence in Molecular Systems ImmunologyAcademy of Finland Decision No. 250114Academy of Finland Physiology Research 2012-2017Alfred Kordelinin Säätiö 200356Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9E082Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9F089Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9G087Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9H092Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9J147Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9K149Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9L042Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9L117Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9M114Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9N086Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9P057Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9R055Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9S074Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9U065Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital 9V072European Comission BMH4-CT98-3314JDRF International 1-SRA-2016-342-M-RJDRF International 1-SRA-2019-732-M-BJDRF International 3-SRA-2020-955-S-BJDRF International 4-1998-274JDRF International 4-1999-731JDRF International 4-2001-435Turun Yliopistollinen Keskussairaala state research funding VTR)
6 · The paper itself

Abstract

In many populations, the peak period of incidence of type 1 diabetes (T1D) has been observed to be around 10-14 years of age, coinciding with puberty, but direct evidence of the role of puberty in the development of T1D is limited. We therefore aimed to investigate whether puberty and the timing of its onset are associated with the development of islet autoimmunity (IA) and subsequent progression to T1D. A Finnish population-based cohort of children with HLA-DQB1-conferred susceptibility to T1D was followed from 7 years of age until 15 years of age or until a diagnosis of T1D (n = 6920). T1D-associated autoantibodies and growth were measured at 3- to 12-month intervals, and pubertal onset timing was assessed based on growth. The analyses used a three-state survival model. IA was defined as being either positive for islet cell antibodies plus at least one biochemical autoantibody (ICA + 1) or as being repeatedly positive for at least one biochemical autoantibody (BC1). Depending on the IA definition, either 303 (4.4%, ICA + 1) or 435 (6.3%, BC1) children tested positive for IA by the age of 7 years, and 211 (3.2%, ICA + 1)) or 198 (5.3%, BC1) developed IA during follow-up. A total of 172 (2.5%) individuals developed T1D during follow-up, of whom 169 were positive for IA prior to the clinical diagnosis. Puberty was associated with an increase in the risk of progression to T1D, but only from ICA + 1-defined IA (hazard ratio 1.57; 95% confidence interval 1.14, 2.16), and the timing of pubertal onset did not affect the association. No association between puberty and the risk of IA was detected. In conclusion, puberty may affect the risk of progression but is not a risk factor for IA.

Indexed as

Diabetes Mellitus, Type 1Islets of LangerhansAdolescentAutoantibodiesAutoimmunityChildDisease ProgressionHumansPubertyAutoantibodiesCohort studyIslet autoimmunityMulti-state modelPubertyType 1 diabetes

Identifiers

PMID37079135
PMCPMC10232567
OpenAlexW4366463624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.